Sorrento Announces IND Filing for COVI-DROPS, an Intranasal Formulation of a High Potency Neutralizing Antibody Against SARS-CoV-2

    NEXT STORY
    Seasonal Probiotics Company Jetson Adds Leading Pediatrician and OBGYN to Advisory “Gut Council”
    PREV STORY
    Bellerophon to Present at the H.C. Wainwright 6th Annual Israel Conference
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Cyclacel Pharmaceuticals to Release First Quarter 2016 Financial Results

    BERKELEY HEIGHTS, N.J., May 04, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ...

    author_avatar
    NASDAQ Market News

    EyeGate Pharma Enrolls First Patient in Confirmatory Phase 3 Clinical Trial EGP-437-006 for Non-Infectious Anterior Uveitis

    WALTHAM, Mass., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or ...

    author_avatar
    NASDAQ Market News

    Novartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS)

    author_avatar
    NASDAQ Market News